In early September, 15-year-old gene therapy developer Precision BioSciences devoted its entire two-hour R&D presentation to products in its pipeline that involve in vivo gene editing—therapies ...
2023 was an important year for patients with sickle cell disease. Prior to CRISPR, the only cure for the life-long ailment was a bone marrow transplant, which is notoriously dangerous and costly. This ...
Every time Andrew publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
Ten years ago, a little-known Science paper authored by Jennifer Doudna, Ph.D., and Emmanuelle Charpentier, Ph.D., proposed using CRISPR/Cas9 for gene editing. As the first wave of gene-editing-based ...
Geulah Livshits, PhD, a Senior Research Analyst at Chardan covering biotech companies, with a focus on gene editing and oncology. Genome editing’s dazzling potential and stubborn challenges were both ...
Wall Street analysts have painted a tantalizing picture of triple-digit upside potential for some of this year’s worst-performing biotech names. Yet investors may want to temper their excitement.
From model development to testing innovative gene editing-based therapeutic approaches, Lobna Elkhadragy explains how CRISPR gene editing in large animals offers exciting opportunities in biomedical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback